Spruce Biosciences, Inc. (SPRB)

USD 0.31

(8.04%)

Market Cap (In USD)

12.98 Million

Revenue (In USD)

10.08 Million

Net Income (In USD)

-47.91 Million

Avg. Volume

314.8 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.37-5.95
PE
-0.33
EPS
-0.95
Beta Value
2.369
ISIN
US85209E1091
CUSIP
85209E109
CIK
1683553
Shares
41302600.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Javier Szwarcberg M.D., M.P.H.
Employee Count
-
Website
https://www.sprucebiosciences.com
Ipo Date
2020-10-09
Details
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.